


PHARMACEUTICAL 2023

Alzamend Neuro Inc. Rank 170 of 446





PHARMACEUTICAL 2023

Alzamend Neuro Inc. Rank 170 of 446

The relative strengths and weaknesses of Alzamend Neuro Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alzamend Neuro Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 101% points. The greatest weakness of Alzamend Neuro Inc. is the variable Net Income, reducing the Economic Capital Ratio by 77% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 92% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,414
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,165
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-43
Other Revenues	0
Property and Equipment	103
Research and Development	5,201
Selling, General and Administrative Expense	7,118

Output Variable	Value in 1000 USD
Assets	14,516
Liabilities	1,165
Expenses	12,320
Revenues	0
Stockholders Equity	13,352
Net Income	-12,362
Comprehensive Net Income	-12,362
Economic Capital Ratio	135%

